Venture-backed company Aterovax is offering its proprietary atherosclerosis biomarker for use in pharma clinical research, through a collaboration with Biomnis, a provider of medical testing and pathology services. The biomarker is related to the phospholipases A2 (PLA2) superfamily of ...
Please Login to read the full article.
